Genesco (GCO) Tops Q4 EPS by 34c, Offers FY21 Guidance

Genesco (NYSE: GCO) reported Q4 EPS of $3.09, $0.34 better than the analyst estimate of $2.75. Revenue for the quarter came in at $678 million versus the consensus estimate of $679.7 million.

GUIDANCE:

Genesco sees FY2021 EPS of $4.90-$5.40, versus the consensus of $4.80.

• Total sales to increase 3% to 6% including sales from the recent Togast acquisition.
• Comparable sales to be down 1% to up 2%, and
• Adjusted diluted earnings per share from continuing operations in the range of $4.90 to $5.40 with an expectation that earnings for the year will be near the midpoint of the range. 2

For earnings history and earnings-related data on Genesco (GCO) click here.

You May Also Be Interested In

• Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
• AdaptHealth Corp. (AHCO) Misses Q3 EPS by 120c ; Offers Guidance
• IPG Photonics (IPGP) Tops Q3 EPS by 15c ; Offers Guidance